King's College London

Research portal

Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)733-734
Number of pages2
JournalAlimentary Pharmacology & Therapeutics
Issue number6
Early online date4 Mar 2022
E-pub ahead of print4 Mar 2022
PublishedMar 2022

Bibliographical note

Funding Information: Declaration of personal interest: Sailish Honap served as a speaker, a consultant, and/or an advisory board member for Pfizer, Janssen, and Takeda. Robin Dart has received research support and/or has received fees for the delivery of non-promotional education or consulting from Gamma Delta Therapeutics, Adaptate Biotherapeutics, Takeda and Janssen. Mark Samaan served as a speaker, a consultant and/or an advisory board member for Sandoz, Janssen, Takeda, MSD, Falk, Abbvie, Bristol Myers Squibb and Samsung Bioepis.

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454